TGM7 and neoplasm: In vivo pharmacokinetics results showed the half-time of TGZ@eM (t1/2 = 4.7) was two times longer than that of TGZ (t1/2 = 2.4), which enhanced the accumulation of TGZ@eM to the tumor.